Respire_final-01
  • CORPORATE
    • Company Overview
    • Company Management
    • Board of Directors
    • Scientific Team Leaders
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • PHARMACEUTICAL CANNABINOIDS
    • Background
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • NEUROMODULATORS
    • Ampakines
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
      • Autism Spectrum Disorder (ASD)
    • GABAkines
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

10/06/2020 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury

October 6, 2020j3ff1

Neurotransmission

  • Neurotransmission
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.